Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03141203Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Primary completion
- Aug 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of romidepsin and carfilzomib in peripheral T-cell lymphoma (PTCL), sponsored by University of Birmingham. Started Jul 2015; status: completed.
02
Drugs
romidepsincarfilzomib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03141203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141203.